Literature DB >> 35507230

Analysis of Opioid Use in Patients Undergoing Open Versus Robotic Gastrectomy.

Yuki Hirata1, Russell G Witt1, Laura R Prakash1, Elsa M Arvide1, Kristen A Robinson1, Vijaya Gottumukkala2, Ching-Wei D Tzeng1, Paul Mansfield1, Brian D Badgwell1, Naruhiko Ikoma3.   

Abstract

BACKGROUND: Minimally invasive, robotic gastrectomy is associated with better short-term outcomes and quicker functional recovery. However, the degree to which the robotic approach influences postoperative pain and opioid use after gastrectomy is unknown. Our primary aim was to determine whether the robotic approach to gastrectomy reduces postoperative opioid use compared with the open approach.
METHODS: Patients who underwent gastrectomy (November 2018 to September 2021) were identified retrospectively. Clinical characteristics, short-term surgical outcomes, oral morphine equivalent (OME) use, and pain scores were collected. Both groups were managed through an enhanced recovery program in the perioperative period.
RESULTS: Of 81 patients, 50 underwent open and 31 underwent robotic gastrectomy. Compared with open gastrectomy patients, robotic gastrectomy patients had longer surgery time (360 vs. 288 min), less blood loss (50 vs. 138 mL), and shorter hospital stay (4 vs. 6 days) (all medians, P < 0.001). Robotic gastrectomy patients used lower OMEs on postoperative days 0-4 (all P < 0.05) and in total for days 0-4 (total mean dose 65.0 vs. 169.5 mg; P < 0.001) than did open gastrectomy patients. The robotic gastrectomy patients were prescribed a lower mean OME dose than the open gastrectomy patients (19.0 vs. 29.0 mg, respectively; P = 0.001). Multivariable analysis showed that robotic approach was associated with lower opioid use (odds ratio 3.70; 95% CI 1.01-14.3; P = 0.049).
CONCLUSIONS: Compared with open gastrectomy, robotic gastrectomy reduces opioid use in the early postoperative period and is associated with fewer OME discharge prescriptions and shorter hospital stay.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35507230     DOI: 10.1245/s10434-022-11836-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  54 in total

1.  Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer: a multi-institutional prospective single-arm study.

Authors:  Ichiro Uyama; Koichi Suda; Masaya Nakauchi; Takahiro Kinoshita; Hirokazu Noshiro; Shuji Takiguchi; Kazuhisa Ehara; Kazutaka Obama; Shiro Kuwabara; Hiroshi Okabe; Masanori Terashima
Journal:  Gastric Cancer       Date:  2018-12-03       Impact factor: 7.370

2.  Opioid utilization in minimally invasive versus open inguinal hernia repair.

Authors:  Ariel W Knight; Elizabeth B Habermann; Daniel S Ubl; Martin D Zielinski; Cornelius A Thiels
Journal:  Surgery       Date:  2019-06-20       Impact factor: 3.982

Review 3.  Robotic surgery for gastric cancer.

Authors:  Masanori Terashima; Masanori Tokunaga; Yutaka Tanizawa; Etsuro Bando; Taaichi Kawamura; Yuichiro Miki; Rie Makuuchi; Shinsaku Honda; Taichi Tatsubayashi; Wataru Takagi; Hayato Omori; Fumiko Hirata
Journal:  Gastric Cancer       Date:  2015-04-22       Impact factor: 7.370

Review 4.  Non-opioid pain management in benign minimally invasive hysterectomy: A systematic review.

Authors:  Emily Blanton; Georgine Lamvu; Insiyyah Patanwala; Kenneth I Barron; Kathryn Witzeman; Frank F Tu; Sawsan As-Sanie
Journal:  Am J Obstet Gynecol       Date:  2016-12-30       Impact factor: 8.661

5.  Perioperative pain after robot-assisted versus laparoscopic rectal resection.

Authors:  Rikke Tolstrup; Jonas Amstrup Funder; Liselotte Lundbech; Niels Thomassen; Lene Hjerrild Iversen
Journal:  Int J Colorectal Dis       Date:  2017-12-14       Impact factor: 2.571

6.  Opioid-free colorectal surgery: a method to improve patient & financial outcomes in surgery.

Authors:  Deborah S Keller; Jianying Zhang; Manish Chand
Journal:  Surg Endosc       Date:  2018-10-17       Impact factor: 4.584

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

9.  TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Authors:  Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong
Journal:  BMC Cancer       Date:  2015-07-21       Impact factor: 4.430

10.  PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.

Authors:  Yoon-Koo Kang; Jeong Hwan Yook; Young-Kyu Park; Jong Seok Lee; Young-Woo Kim; Jin Young Kim; Min-Hee Ryu; Sun Young Rha; Ik Joo Chung; In-Ho Kim; Sang Cheul Oh; Young Soo Park; Taeil Son; Mi Ran Jung; Mi Hwa Heo; Hark Kyun Kim; ChoHyun Park; Chang Hak Yoo; Jin-Hyuk Choi; Dae Young Zang; You Jin Jang; Ji Young Sul; Jong Gwang Kim; Beom Su Kim; Seung-Hoon Beom; Sang Hee Cho; Seung Wan Ryu; Myeong-Cherl Kook; Baek-Yeol Ryoo; Hyun Ki Kim; Moon-Won Yoo; Nam Su Lee; Sang Ho Lee; Gyunji Kim; YeonJu Lee; Jee Hyun Lee; Sung Hoon Noh
Journal:  J Clin Oncol       Date:  2021-06-16       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.